MAKO Surgical (Nasdaq: MAKO) is expected to report Q2 earnings on Aug. 1. Here's what Wall Street wants to see:

The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict MAKO Surgical's revenues will increase 27.3% and EPS will remain in the red.

The average estimate for revenue is $23.7 million. On the bottom line, the average EPS estimate is -$0.22.

Revenue details
Last quarter, MAKO Surgical logged revenue of $19.6 million. GAAP reported sales were 51% higher than the prior-year quarter's $13.0 million.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
Last quarter, EPS came in at -$0.28. GAAP EPS were -$0.28 for Q1 versus -$0.27 per share for the prior-year quarter.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Recent performance
For the preceding quarter, gross margin was 72.1%, 350 basis points better than the prior-year quarter. Operating margin was -59.9%, 2,490 basis points better than the prior-year quarter. Net margin was -59.7%, 2,470 basis points better than the prior-year quarter.

Looking ahead
The full year's average estimate for revenue is $109.0 million. The average EPS estimate is -$0.79.

Investor sentiment
The stock has a four-star rating (out of five) at Motley Fool CAPS, with 1,126 members out of 1,167 rating the stock outperform, and 41 members rating it underperform. Among 252 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 238 give MAKO Surgical a green thumbs-up, and 14 give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on MAKO Surgical is hold, with an average price target of $42.25.

The healthcare investing landscape is littered with also-rans and a few major winners. Is MAKO Surgical the right stock for you? Read "Discover the Next Rule-Breaking Multibagger" to learn about a company David Gardner believes will be a phenomenal success over the next few years. Click here for instant access to this free report.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.